Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 28 of 45

Comparative Adverse Effects of Biologic DMARDs (2 of 3)

The systematic review investigated adverse effects associated with biologic disease-modifying anti-rheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Mixed treatment comparison analysis of data from placebo-controlled trials of biologic DMARDs (43 trials, 19,413 patients) provided the basis for the following conclusions:

  • Certolizumab pegol, etanercept, and rituximab have more favorable overall treatment withdrawal profiles than other biologic DMARDs. The strength of evidence for this finding is low.
  • Withdrawal from treatment due to adverse events is more likely with certolizumab pegol and infliximab than with etanercept or rituximab. The strength of evidence for this finding is low.
  • Withdrawals from treatment due to injection site reactions are more likely with anakinra, and infliximab is associated with a higher rate of infusion reactions. The strength of evidence for these findings is low.